Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer Cells and Organotypic Tumor Slice Culture.

Researchers found that masitinib mesylate, an existing drug, inhibits FOXM1—a cancer-promoting protein—and reduced cancer cell growth, stemness, and migration in breast and oral cancer models, including patient-derived tumor tissues.

A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.